.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR19_EmtricitabineTenofovirAl.EmtricitabineTenofovirAl .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR19_EmtricitabineTenofovirAl.EmtricitabineTenofovirAl| name: | EmtricitabineTenofovirAlafenamideAndRilpivirine | |
| ATC code: | J05AR19 | route: | oral |
| compartments: | 1 | |
| dosage: | 200 | mg |
| volume of distribution: | 1.4 | L |
| clearance: | 25 | L/h |
| other parameters in model implementation | ||
Fixed-dose combination tablet containing emtricitabine (NRTI), tenofovir alafenamide (NRTI prodrug), and rilpivirine (NNRTI); used as a complete regimen for the treatment of HIV-1 infection in adults and adolescents. The drug is currently approved for clinical use for HIV-1 management.
Pharmacokinetic parameters estimated for healthy adult HIV-negative volunteers after single-dose oral administration. Parameter values are approximated based on separate published PK profiles for each component, as no population PK publication exists for the fixed combination product.